VCYT (Veracyte) EPS without NRI: $2.00 (TTM As of Mar. 2026)


VCYT Veracyte Inc VCYT
75 GF Score
Price $58.73
GF Value $38.11
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Veracyte EPS without NRI?

Veracyte VCYT -2.43% 75 EPS without NRI is $2.00 as of Mar. 2026. GuruFocus rates VCYT with a GF Score™ of 75/100 and a GF Value™ of $38.11 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 161 Medical Diagnostics & Research companies, Veracyte ranks worse than 621117.39% on this metric.

Veracyte's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $0.52. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $2.00.

During the past 12 months, Veracyte's average earnings per share (NRI) Growth Rate was 53.80% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Veracyte's EPS without NRI or its related term are showing as below:

During the past 13 years, Veracyte's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 44.00% per year. The lowest was -20.90% per year. And the median was 11.30% per year.

VCYT's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 10.8
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Veracyte's EPS (Diluted) for the three months ended in Mar. 2026 was $0.35. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $1.09.

Veracyte's EPS (Basic) for the three months ended in Mar. 2026 was $0.36. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $1.11.


Veracyte  (NAS:VCYT) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Veracyte EPS without NRI Related Terms


Veracyte EPS without NRI Historical Data

* Premium members only.

The historical data trend for Veracyte's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veracyte EPS without NRI Chart

Veracyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.10 -0.48 -0.12 1.19 1.78

Veracyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.44 0.51 0.53 0.52

VCYT vs RDNT, SHC, BLLN: EPS without NRI Comparison

For the Diagnostics & Research subindustry, Veracyte's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veracyte PE Ratio without NRI vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Veracyte's PE Ratio without NRI falls into.


VCYT
75GF Score
Veracyte Inc VCYT
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veracyte EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $2.00 mean?
Veracyte (VCYT) has a EPS without NRI of $2.00 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Veracyte and its competitors. According to the industry distribution chart, Veracyte ranks #999999 out of 161 companies in the Medical Diagnostics & Research industry.
Is Veracyte's EPS without NRI too high?
Veracyte's current EPS without NRI is $2.00. The Medical Diagnostics & Research industry median EPS without NRI is 10.80. Veracyte's value of $2.00 is 81.5% below this industry median. Based on the distribution chart, Veracyte ranks #999999 out of 161 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Veracyte has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Veracyte's EPS without NRI compare to RDNT and SHC?
According to the Medical Diagnostics & Research industry distribution chart, Veracyte ranks #999999 out of 161 companies for EPS without NRI. This places Veracyte in the lower half of its industry. The industry median EPS without NRI is 10.80. Veracyte's value of $2.00 is 81.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 10.80, based on 161 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veracyte's current EPS without NRI of $2.00 is 81.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Veracyte and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veracyte's current EPS without NRI is $2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veracyte stock overvalued right now?
Based on GuruFocus' analysis, Veracyte (VCYT) is currently considered Significantly Overvalued. The stock's GF Value™ is $38.11, compared to a current price of $58.73 — trading 54.1% above its estimated fair value. The current EPS without NRI is $2.00 and 81.5% below the Medical Diagnostics & Research industry median of 10.80. Veracyte's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Veracyte (VCYT), the current EPS without NRI is $2.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Veracyte (VCYT) Overvalued in 2026?

Based on GuruFocus' analysis, Veracyte stock appears to be overvalued. The current stock price of $58.73 is trading 54.1% above its estimated GF Value™ of $38.11. GuruFocus considers Veracyte to be Significantly Overvalued.

Key valuation signals for VCYT:

  • EPS without NRI: $2.00
  • GF Value™: $38.11 vs. price of $58.73 (54.1% above fair value)
  • GF Score™: 75/100 with 7 warning signs
  • Industry Position: 81.5% below the Medical Diagnostics & Research median (#999999 of 161)

No single metric tells the full story. See the VCYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Veracyte Business Description

Other Exchanges 12V:Germany
Address 6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
75GF Score

Get the complete analysis for VCYT

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$58.73
Price
$38.11
GF Value